Changes in schizophrenia symptoms, tryptophan metabolism, neuroinflammation and the GABA-glutamate loop: A pilot study
Résumé
Methods Study design and assessmentsTwenty-eight black African patients with a diagnosis of schizophrenia (DSM-5 criteria) were recruited upon admission to a psychiatric hospital in the Dr Kenneth Kaunda District, North West province, South Africa, between January 2021 and June 2022.Patients were either newly diagnosed (first-episode psychosis) or had relapsed and had been antipsychotic free (i.e. did not receive any antipsychotics at dosages indicated for antipsychotic effects for at least 6 months prior to admission).Exclusion criteria included non-African descent, neurological disorders, head trauma, pregnancy, lactation, tympanum temperatures >37°C, substance abuse and tested positive for coronavirus disease 2019 (COVID-19).Patients exhibiting destructive, Changes in schizophrenia symptoms, tryptophan metabolism, neuroinflammation and the GABA-glutamate loop: A pilot study Read online:Scan this QR code with your smart phone or mobile device to read online.
Citer ce document
Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)
Accès au document
Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter
Voir l'article sur le site de la revueLicence et provenance
Licence : CC BY
Notice moissonnée depuis OpenAlex le 28/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →